Condition · ICD-11 QC42
Palliative care
Reviewed by Dr. Placeholder E (HPCSA MP0XXXXX · Palliative Care) · Last updated · Published
Palliative care focuses on quality of life and symptom-burden reduction for patients with serious or life-limiting illness — most commonly advanced cancer, end-stage organ failure, and progressive neurological disease. Medical cannabis has a well-established adjunctive role in this setting for refractory pain, intractable nausea, anorexia and cachexia, and treatment-resistant insomnia. Critically, cannabinoid therapy in palliative care is not curative and not framed as therapy against the underlying illness — it is comfort care, integrated with the broader palliative-care plan and coordinated with the patient's palliative team.
What the evidence says
Bar-Lev Schleider et al (2018) reported a large Israeli prospective cohort of cancer-symptom patients (many palliative) finding meaningful improvement in pain, sleep, appetite, and global wellbeing under medical-cannabis treatment. Mücke et al (2018 Cochrane) reviewed cannabinoids in palliative care and concluded the evidence quality is low-to-moderate but consistent enough to support cautious use as adjunctive therapy. WHO palliative-care frameworks recognise cannabinoids as a reasonable option in refractory symptom-burden where conventional approaches are inadequate. The honest summary: in advanced-illness comfort care, the bar for trying an additional symptomatic option is lower than in disease-modifying contexts, and cannabinoids are a reasonable late-stage adjunct.
How the doctor will evaluate you
In palliative-care contexts, the doctor will require involvement of (or at least notification to) the palliative-care team or treating specialist. The clinical question is rarely "should we add cannabinoids" — it is "which symptom dominates and what is the most appropriate format". For pain and nausea, a balanced THC:CBD oil is common. For end-of-life dyspnoea or restlessness, oromucosal formulations may be preferred. Doses are usually conservative and titrated rapidly, since time-to-benefit matters more than long-term tolerance. Caregiver involvement in dosing and adverse-event reporting is often part of the plan.
When to see a doctor urgently
- Lack of coordination with the palliative-care team — cannabinoid prescribing in isolation is inappropriate
- Acute reversible cause of symptom burden (e.g. infection, electrolyte disturbance) — investigate first
- Severe respiratory compromise — inhaled formulations are unsuitable; oral or oromucosal preferred
- Patient or caregiver framing cannabinoids as anti-tumour or curative — gentle re-framing is part of the consultation
If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.
The South African Section 21 pathway
Palliative-care cannabinoid prescribing is a recognised use of the SA Section 21 pathway. Applications carry weight when accompanied by palliative-team correspondence, a clear dominant-symptom rationale, and a documented trial of conventional comfort measures (titrated opioids, antiemetics, anxiolytics) where appropriate. SAHPRA generally turns these around within standard timelines; doctors often request expedited review where the clinical context is urgent.
Frequently asked
- Is medical cannabis treating the underlying illness?
- No. In palliative care, cannabinoids are adjunctive comfort care — for pain, nausea, appetite, sleep, or anxiety. They are not therapy against the underlying cancer, organ failure, or neurological disease. Honest framing on this matters; it shapes expectations for the patient and family.
- Can it be used alongside opioid pain medication?
- Yes, and it commonly is. The combination can sometimes allow opioid dose reduction or improve symptom control without dose escalation. The doctor will coordinate with whoever prescribes the opioid regimen and adjust slowly — sudden changes in either medication risk loss of pain control.
- Who manages the cannabinoid prescription day-to-day in palliative care?
- In practice this is shared. The Docto24 doctor handles initial assessment and Section 21 application; ongoing day-to-day management is best coordinated with the palliative-care team, treating specialist, or family doctor — particularly where the patient is housebound or in a hospice setting. We supply the prescribing infrastructure; we do not replace the in-person palliative team.
- Is this appropriate if my prognosis is months rather than weeks?
- Yes. Cannabinoid adjunct in palliative care is not reserved for end-of-life only. Patients with months or longer prognosis often benefit from improved pain, sleep, and appetite over a sustained window. The framework is the same — symptom-burden focused, coordinated with the palliative team — but the dosing strategy may emphasise tolerability for longer-term use.
- Can family members be trained to administer the medication?
- Yes. For patients who are unable to self-administer (typically late-stage), caregiver training on dosing, timing, and adverse-event recognition is part of the plan. The dispensing pharmacy provides labelled measuring devices and written instructions; the prescribing doctor remains accessible for caregiver questions during the prescription window.
Related conditions
Glossary — terms used on this page
Quick definitions for terminology referenced above. Each links to a fuller entry.
- THC (Δ⁹-tetrahydrocannabinol)The principal psychoactive cannabinoid in the cannabis plant.
- CBD (cannabidiol)Non-psychoactive cannabinoid with established use in some seizure disorders and emerging use in anxiety.
- OromucosalAbsorption via the lining of the mouth — faster onset than oral, slower than inhaled.
- Full-spectrum vs isolateExtraction categories: full-spectrum contains the plant’s cannabinoids + terpenes; isolate is purified single-cannabinoid.
Think this might apply to you? An HPCSA-registered doctor will review your case.
START ELIGIBILITY REVIEWR500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end